Announced details
Pediatric myopia management and suppression of myopia progression
At 12 months, the mean change in cycloplegic spherical equivalent was −0.35 D in the combination-therapy group and −0.63 D in the atropine-only group, a difference of 0.28 D. Mean axial elongation was 0.25 mm and 0.28 mm, respectively, a difference of 0.03 mm. In the 6-month questionnaire, 94% of respondents said they would be willing to use the device if it could suppress myopia progression.
28 study participants at baseline. The 12-month assessment included 15 participants in the combination-therapy group and 8 in the monotherapy group. The 6-month questionnaire included 18 participants.
The company's consolidated subsidiary Kubota Vision Inc. will present the study results at the conference. In terms of capital relationships, Kubota Vision Inc. is the company's consolidated subsidiary.
An academic organization in optometry and vision science that holds the annual meeting “Academy 2026 Anaheim.” Other information, including its location, representative, capital and year established, is Not disclosed.
Hsinchu City, Taiwan: China Medical University Hsinchu Hospital
The transaction will have no impact on the company's consolidated financial results.
The company does not address Contract Value / Offering price.
Zadnik K, Schulman E, Flitcroft I, et al. JAMA Ophthalmol. 2023
Repka MX, Weise KK, Chandler DL, et al. JAMA Ophthalmol. 2023
| Item | Details |
|---|---|
| Names of Products / Services Covered | Kubota Glass, Kubota Glass Technology |
| Counterparty | American Academy of Optometry |
| Counterparty overview | An academic organization in optometry and vision science that holds the annual meeting “Academy 2026 Anaheim.” Other information, including its location, representative, capital and year established, is Not disclosed. |
| Relationship with the Company | The company's consolidated subsidiary Kubota Vision Inc. will present the study results at the conference. In terms of capital relationships, Kubota Vision Inc. is the company's consolidated subsidiary. |
| Launch date | 1 October 2026 (scheduled, poster presentation date) |
| Applicable area | Pediatric myopia management and suppression of myopia progression |
| Location | Hsinchu City, Taiwan: China Medical University Hsinchu Hospital |
| Quantitative Effects | At 12 months, the mean change in cycloplegic spherical equivalent was −0.35 D in the combination-therapy group and −0.63 D in the atropine-only group, a difference of 0.28 D. Mean axial elongation was 0.25 mm and 0.28 mm, respectively, a difference of 0.03 mm. In the 6-month questionnaire, 94% of respondents said they would be willing to use the device if it could suppress myopia progression. |
| Usage history | 28 study participants at baseline. The 12-month assessment included 15 participants in the combination-therapy group and 8 in the monotherapy group. The 6-month questionnaire included 18 participants. |
| Impact on Business Performance | The transaction will have no impact on the company's consolidated financial results. |
| Source | Zadnik K, Schulman E, Flitcroft I, et al. JAMA Ophthalmol. 2023, Repka MX, Weise KK, Chandler DL, et al. JAMA Ophthalmol. 2023 |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because study results on the efficacy of low-dose atropine have been mixed, the study examined whether combining treatments with different mechanisms of action could provide a new option for myopia management and sought information useful for planning larger randomized clinical trials in the future.